[拓扑异构酶IIα作为胃淋巴瘤增殖因子的免疫组织化学评估]
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma].
作者信息
Ferariu D, Danciu M, Ciobanu Delia, Zugun F, Florea Niculina, Mihailovici Maria Sultana
机构信息
Serviciul de Anatomie Patologică si Prosectură, Spitalul Clinic de Urgenţă "Sf. Spiridon" Iaşi.
出版信息
Rev Med Chir Soc Med Nat Iasi. 2008 Jul-Sep;112(3):738-43.
UNLABELLED
Topoisomerase IIalpha is a nuclear enzyme essential for DNA replication, with presumed prognostic value in various tumors.
MATERIAL AND METHODS
Study group included 34 gastric lymphomas. Tissue samples, formalin-fixed, paraffin-embedded, were investigated by immunhistochemistry using monoclonal antibodies anti Ki67 and anti topoisomerase IIalpha.
RESULTS
The 34 gastric lymphomas were previously diagnosed as follows: 14 MALT lymphoma and 20 aggressive lymphoma (17 diffuse large B-cell lymphoma, 2 diffuse large B-cell lymphoma with minor MALT component and 1 peripheral T-cell lymphoma). Both markers (Ki67 and topoisomerase IIalpha) were positive in 2-31% of tumor cells in MALT lymphoma, while in aggressive lymphoma up to 46-98% of tumor cells showed a positive expression.
CONCLUSION
Similar expression of Ki67 and topoisomerase IIalpha recommends the utilization of topoisomerase IIalpha in determining the proliferation fraction in gastric lymphomas. In addition, we suggest that it might be possible to use topoisomerase II inhibitor agents in high grade gastric lymphomas.
未标记
拓扑异构酶IIα是一种对DNA复制至关重要的核酶，在各种肿瘤中具有推测的预后价值。
材料与方法
研究组包括34例胃淋巴瘤。采用抗Ki67和抗拓扑异构酶IIα单克隆抗体，通过免疫组织化学对福尔马林固定、石蜡包埋的组织样本进行研究。
结果
34例胃淋巴瘤先前诊断如下：14例黏膜相关淋巴组织（MALT）淋巴瘤和20例侵袭性淋巴瘤（17例弥漫性大B细胞淋巴瘤、2例伴有少量MALT成分的弥漫性大B细胞淋巴瘤和1例外周T细胞淋巴瘤）。在MALT淋巴瘤中，两种标志物（Ki67和拓扑异构酶IIα）在2% - 31%的肿瘤细胞中呈阳性，而在侵袭性淋巴瘤中，高达46% - 98%的肿瘤细胞呈阳性表达。
结论
Ki67和拓扑异构酶IIα的相似表达表明在确定胃淋巴瘤的增殖分数时可利用拓扑异构酶IIα。此外，我们建议在高级别胃淋巴瘤中可能可以使用拓扑异构酶II抑制剂。
Zotero 插件